Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.
 
> α-Phellandrene [99-83-2]

α-Phellandrene [99-83-2]

Imprimer Imprimer
Identifiez-vous

Référence HY-121615-10g

Conditionnement : 10g

Marque : MedChemExpress


Description

α-Phellandrene (alpha-Phellandrene) is an orally active monoterpenoid and insecticide. α-Phellandrene can be isolated from plant essential oils. α-Phellandrene induces Apoptosis and Autophagy. α-Phellandrene promotes cAMP signaling pathway and increases NO production. α-Phellandrene has anti-inflammatory and anticancer (sarcoma) activities. α-Phellandrene shows insecticidal activity against Lucilia cuprina L3. α-Phellandrene reduces mechanical hyperalgesia[1][2][3][4][5][6][7][8][9][10][11].

In Vitro

α-Phellandrene (10-200 μM; 16 h) significantly enhances the proliferation and migration of L929 fibroblasts in a dose-dependent manner[1].
α‑Phellandrene (50-250 μM; 72 h) enhances the apoptosis of HT‑29 cells induced by 5‑fluorouracil (HY-90006) by modulating the mitochondria‑dependent pathway[2].
α-Phellandrene (30 μM; 24 h) significantly increases the necrotic cell number, NO production, LDH leakage and ATP depletion in J5 cells[3].
α-Phellandrene (10 μM; 48 h) alters expression of genes associated with DNA damage, cell cycle, and apoptosis in murine leukemia WEHI-3 cells[4].
α-Phellandrene (12.5 μM; 48 h) promotes dermal papilla cell proliferation via promoting cAMP signaling pathway[5].
α-Phellandrene (10-50 μM; 24 h) induces autophagy in human liver cancer J5 cells, as indicated by an increase in autophagic vacuole staining[6].
α-Phellandrene (0.29-1.47 μL/cm2) inhibits the emergence of adult Lucilia cuprina L3 larvae, causes damage to the larval body surface and induces histological changes in target organs such as the digestive tract, fat body, and brain of the larvae[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

α-Phellandrene Related Antibodies

Western Blot Analysis[3]

Cell Line: J5 cells
Concentration: 30 μM
Incubation Time: 6, 12, 24 h
Result: Had no significant effect on the protein expressions of Bax, Bcl-2, full-length PARP and caspase-3 activity.
In Vivo

α-Phellandrene (1-25 mg/kg; p.o.; daily; 27 days) promotes immune responses in normal mice through enhancing macrophage phagocytosis and natural killer cell activities[8].
α-Phellandrene (6.25-50 mg/kg; p.o.; acute assay starts on day 8 after inoculation with S-180; the early regimen is once daily for 8 days; subacute experiment begins on the 17th day) inhibits tumor growth in mice inoculated with Sarcoma 180 cells, reduces mechanical hyperalgesia, decreases direct (peritumoral tissue in the subaxillary region) and indirect (right leg) mechanical nociception[9].
α-Phellandrene (6.25-100 mg/kg; i.p.; 30 min before the administration of Ifosfamide) attenuates tissular damage, oxidative stress, and TNF-α levels on acute model Ifosfamide (HY-17419)-induced hemorrhagic cystitis in mice[10].
α-Phellandrene (50-200 mg/kg; p.o.; 1 h before subsequent experiments) attenuates inflammatory response through neutrophil migration inhibition and mast cell degranulation in Wistar rats or Swiss mice[11].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male BALB/c mice (aged eight weeks, around 22-25 g in weight)[8]
Dosage: 1 mg/kg, 5 mg/kg, 25 mg/kg (dissolved in olive oil)
Administration: Oral gavage, daily for 27 days
Result: Affected the cell population of normal mice.
Increased the levels of CD3 at 1 mg/kg, increased CD19 level at 5 and 25 mg/kg, and increased Mac-3 level at 25 mg/kg.
Significantly suppressed the CD11b level at 5 and 25 mg/kg.
Promoted phagocytotic activity of macrophages obtained from PBMCs at 5 and 25 mg/kg.
Promoted NK cell activity and B- and T-cell proliferation at 25 mg/kg.
Masse moléculaire

136.23

Formule

C10H16
CAS No.
Appearance

Liquid (Density: 0.848 g/cm3)

Color

Colorless to light yellow

SMILES

CC1=CCC(C=C1)C(C)C
Structure Classification
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Solvant et solubilité
In Vitro: 

DMSO : 200 mg/mL (1468.11 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 7.3405 mL 36.7026 mL 73.4053 mL
5 mM 1.4681 mL 7.3405 mL 14.6811 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (18.35 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.5 mg/mL (18.35 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Pureté et documentation
Références